Generic Name and Formulations:
Insulin detemir (rDNA origin) 100 Units/mL; SC inj; contains zinc, m-cresol.
Indications for LEVEMIR:
Type 1 diabetes (in adults and children) and type 2 diabetes (in adults) when basal (long-acting) insulin is needed.
Limitations Of use:
Not for treating diabetic ketoacidosis.
Limitations Of use:
Not for treatment of diabetic ketoacidosis.
Adults and Children:
May be given once daily with evening meal or at bedtime or twice-daily (in the AM and PM). SC inj only into thigh, abdominal wall, or upper arm. <2yrs: not recommended. ≥2yrs, type 1 diabetes: starting dose should be ⅓ of total daily insulin requirements; rapid-acting or short-acting, pre-meal insulin should be used to satisfy remainder of daily insulin requirements. Insulin-naive, type 2 diabetic adults inadequately controlled on oral antidiabetics: initially 10 Units (or 0.1–0.2 Units/kg) once daily in the evening or divided into twice daily regimen; inadequately controlled on GLP-1 receptor agonist: initially 10 Units once daily in the evening. Switching from another basal insulin: dose should be the same on a unit-to-unit basis; may need more insulin detemir when switching from NPH (see full labeling).
Instruct patients on diet, exercise, blood or urine testing, proper administration of insulin, change in species of origin, type or purity of insulin, and management of hypoglycemia. Do not reuse or share pens, needles, or syringes between patients. Dosage increase may be required during infection, illness, stress, trauma, and pregnancy. Dosage decrease may be needed with renal or hepatic dysfunction. Pregnancy (Cat.B). Nursing mothers.
Do not mix or dilute with other insulins. Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, pramlintide, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by corticosteroids, isoniazid, niacin, danazol, diuretics, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, atypical antipsychotics. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine.
Hypoglycemia, hypokalemia, local or systemic allergy, lipodystrophy, edema.
Vials (10mL)—1; FlexTouch (3mL)—1
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- Finding Clinical Trials in Cancer
- Adding Nintedanib Did Not Improve Survival in Lung Cancer Subtype
- The Identification of a Potential Early Plasma Biomarker for Kidney Cancer
- Pembrolizumab Plus Chemotherapy Extended Survival Longer Than Chemotherapy Alone: Study
- Combining Chemotherapy With Checkpoint Inhibitors Extends Overall Survival in ES-SCLC
- In a Head-to-Head Battle, Brigatinib Appears to Best Crizotinib